Search
Search Results
-
HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
BackgroundPrevious studies have indicated that HBV pregenome RNA (HBV pgRNA) could predict HBeAg seroconversion among the chronic hapatitis B (CHB)...
-
HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B
BackgroundThe role of neutrophils in hepatitis B virus (HBV) infection has been a subject of debate due to their involvement in antiviral responses...
-
Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection
PurposeMother-to-child transmission (MTCT) has been the main cause of chronic hepatitis B virus (HBV) infection, particularly in East Asia. Hepatitis...
-
When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?
Purpose of ReviewThe strategy of finite nucleos(t)ide analogue (Nuc) therapy in HBeAg-negative patients has been increasingly accepted globally, and...
-
Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B
Background and aimsIn chronic hepatitis B virus (HBV) infection, earlier seroclearance of hepatitis B e antigen (HBeAg) is associated with more...
-
Low positivity rates for HBeAg and HBV DNA in rheumatoid arthritis patients: a case–control study
BackgroundThe rates of hepatitis B virus (HBV) infection in rheumatoid arthritis (RA) patients are controversial when considering the reported...
-
Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study
IntroductionAlthough the indications for antiviral therapy for patients with chronic hepatitis B have been gradually expanded in different...
-
The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
Background and objectivesPegylated interferon alpha-2a (peg-IFN α-2a) and entecavir (ETV) are both recommended as the first-line antiviral drugs for...
-
Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study
BackgroundThere are inadequate data and no histological evidence regarding the effects of antiviral treatment for hepatitis B e-antigen...
-
HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis
BackgroundWe and others have confirmed activation of macrophages plays a critical role in liver injury and fibrogenesis during HBV infection. And we...
-
Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy
Background & aimsThis study aimed to establish multivariate prediction models according to a response-guided therapy (RGT) based strategy at baseline...
-
Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B
Background/aimsWe aimed to explore long-term results of oral antiviral agents in treatment-naïve “HBeAg negative chronic hepatitis B (CHB)” and...
-
Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
BackgroundTenofovir disoproxil fumarate (TDF) is widely used and recommended as first-line treatment for patients infected with the hepatitis B virus...
-
Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial
IntroductionHepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis B e antigen (HBeAg)-negative patients with chronic...
-
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B
ObjectiveWe aimed to assess liver histological changes of HBeAg-negative chronic hepatitis B (CHB) patients with normal ALT, and determined the...
-
Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients
BackgroundViral quasispecies dynamics between pre- and post-nucleos(t)ide analog (NA) therapy remains unclear.
AimThis study aimed to investigate...
-
HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
BackgroundNucleos(t)ide analogues (NAs) cessation is not widely practiced and remains a controversial, but highly relevant subject in patients...
-
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial
Background and aimTraditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this...
-
Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
Background/AimsWe investigated the efficiency of the indirect ratio of anti-HBc IgG at predicting HBsAg seroclearance in patients with nucleos(t)ide...
-
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
BackgroundEvaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic...
